Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer

被引：0
|
作者：
Mattos, Bruna RaphaeliSilva [1 ]
Cesca, Marcelle Goldner [1 ]
Leite, Luciana de Moura [1 ]
Tavares, Monique Celeste [1 ]
Silva, Sinara Figueiredo [1 ]
Pirolli, Rafaela [1 ]
Fogassa, Camilla AlbinaZanco [1 ]
Silva, Erick Figueiredo [1 ]
Rocha, Francisca Giselle [1 ]
Loose, Simone Klug [1 ]
Campos, Fernando AugustoBatista [1 ]
Sanches, Solange Moraes [1 ]
de Lima, Vladmir ClaudioCordeiro [1 ]
Ponde, Noam Falbel [1 ]
机构：
[1] AC Camargo Canc Ctr, Sao Paulo, Brazil
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS4-40
引用
收藏
页数：2
相关论文
共 50 条
  • [1] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    Luciana de Moura Leite
    Marcelle Goldner Cesca
    Monique Celeste Tavares
    Debora Maciel Santana
    Erick Figueiredo Saldanha
    Paula Tavares Guimarães
    Daniella Dias Silva Sá
    Maria Fernanda Evangelista Simões
    Rafael Lima Viana
    Francisca Giselle Rocha
    Simone Klog Loose
    Sinara Figueiredo Silva
    Rafaela Pirolli
    Camilla Albina Zanco Fogassa
    Bruna Raphaeli Silva Mattos
    Fernando Augusto Batista Campos
    Solange Moraes Sanches
    Vladmir Cláudio Cordeiro de Lima
    Noam Falbel Pondé
    Breast Cancer Research and Treatment, 2021, 190 : 155 - 163
  • [2] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    de Moura Leite, Luciana
    Cesca, Marcelle Goldner
    Tavares, Monique Celeste
    Santana, Debora Maciel
    Saldanha, Erick Figueiredo
    Guimaraes, Paula Tavares
    Sa, Daniella Dias Silva
    Simoes, Maria Fernanda Evangelista
    Viana, Rafael Lima
    Rocha, Francisca Giselle
    Loose, Simone Klog
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla Albina Zanco
    Mattos, Bruna Raphaeli Silva
    Campos, Fernando Augusto Batista
    Sanches, Solange Moraes
    de Lima, Vladmir Claudio Cordeiro
    Ponde, Noam Falbel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (01) : 155 - 163
  • [3] Methodology Used to Determine HER2 Status Correlates with Response to Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer
    Cheng, Esther
    McIntire, Patrick
    D'Alfonso, Timothy
    Ginter, Paula
    MODERN PATHOLOGY, 2018, 31 : 54 - 54
  • [4] Methodology Used to Determine HER2 Status Correlates with Response to Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer
    Cheng, Esther
    McIntire, Patrick
    D'Alfonso, Timothy
    Ginter, Paula
    LABORATORY INVESTIGATION, 2018, 98 : 54 - 54
  • [5] Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer response
    Brede-Hekimian, Katya
    LANCET, 2012, 379 (9833) : 2237 - 2237
  • [6] Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
    Domergue, Camille
    Martin, Elodie
    Lemarie, Camille
    Jezequel, Pascal
    Frenel, Jean-Sebastien
    Augereau, Paule
    Campone, Mario
    Patsouris, Anne
    CANCERS, 2022, 14 (10)
  • [7] Significance of HER2 Status in Neoadjuvant Chemotherapy for Breast Cancer Patients
    Wang, Chengqin
    Xing, Xiaoming
    Chen, Zhaoxu
    Wei, Zhimin
    Li, Yujun
    LABORATORY INVESTIGATION, 2023, 103 (03) : S226 - S228
  • [8] Response to neoadjuvant chemotherapy among women with triple-negative breast cancer by HER2 expression status
    Budhathoki, Pravash
    Shah, Anish
    Gaire, Suman
    Joshi, Utsav
    Yadav, Siddhartha
    CANCER RESEARCH, 2023, 83 (05)
  • [9] Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status
    Cha, Chihwan David
    Kim, Kyung Eun
    Kim, Jungbin
    Um, Eunhae
    Choi, Nayeon
    Lee, Jungsun
    Gwak, Geumhee
    Kim, Jae Il
    Chung, Min Sung
    NPJ BREAST CANCER, 2025, 11 (01)
  • [10] Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
    Wei, T.
    Wang, D.
    Peng, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S301 - S302
12345